<DOC>
	<DOC>NCT00427882</DOC>
	<brief_summary>Primary: To assess improvement in ejaculation from baseline to the end of treatment (Week 12 or premature withdrawal) with Alfuzosin 10mg OD, using MSHQ score. Secondary: - To evaluate sexual function improvement - To evaluate LUTS (Lower Uninary Tract Symptoms) improvement - To evaluate the association between LUTS severity and sexual function. - To assess the safety and the tolerability of Alfuzosin 10mg OD.</brief_summary>
	<brief_title>Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Patients suffering from moderate to severe lower urinary tract symptoms (LUTS), suggestive of symptomatic Benign Prostatic Hyperplasia (BPH) diagnosed by the Investigator Patients with an IPSS total score ≥ 8 Patients sexually active as defined by at least one of the following activities in the last 4 weeks: intercourse, caressing, foreplay, masturbation Patients with a known history of hepatic or severe renal insufficiency, unstable angina pectoris Patients who had a previous prostate surgery Patients who had a prostate biopsy or minimally invasive procedure within 6 months prior to inclusion Patients with a prostate surgery or minimally invasive procedure during the whole study period Patients with an active urinary tract infection or prostatitis Patients with a neuropathic bladder defined as a spinal injury consequence or related to a neurological disorder or a known residual volume ≥ 350 ml Patients with a diagnosed prostate cancer Patients having received 5areductase inhibitors or LUTS relatedphytotherapy within 6 months prior to inclusion, or a1blockers within 30 days prior to inclusion Patients receiving any treatment for erectile dysfunction (i.e. phosphodiesterase5 inhibitors) at inclusion Patients with a history of postural hypotension or syncope Patients with a known hypersensitivity to alfuzosin The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>